Literature DB >> 12482965

AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR.

Pengfei Li1, Heehyoung Lee, Shaodong Guo, Terry G Unterman, Guido Jenster, Wenlong Bai.   

Abstract

Recent studies suggested that the protection of cell apoptosis by AKT involves phosphorylation and inhibition of FKHR and related FOXO forkhead transcription factors and that androgens provide an AKT-independent cell survival signal in prostate cancer cells. Here, we report receptor-dependent repression of FKHR function by androgens in prostate cancer cells. Transcriptional analysis demonstrated that activation of the androgen receptor caused an inhibition of both wild-type FKHR and a mutant in which all three known AKT sites were mutated to alanines, showing that the repression is AKT independent. In vivo and in vitro coprecipitation studies demonstrated that the repression is mediated through protein-protein interaction between FKHR and the androgen receptor. Mapping analysis localized the interacting domains to the carboxyl terminus between amino acids 350 and 655 of FKHR and to the amino-terminal A/B region and the ligand binding domain of the receptor. Further analysis demonstrated that the activated androgen receptor blocked FKHR's DNA binding activity and impaired its ability to induce Fas ligand expression and prostate cancer cell apoptosis and cell cycle arrest. These studies identify a new mechanism for androgen-mediated prostate cancer cell survival that appears to be independent of the activity of the receptor on androgen response element-mediated transcription and establish FKHR and related FOXO forkhead proteins as important nuclear targets for both AKT-dependent and -independent survival signals in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12482965      PMCID: PMC140652          DOI: 10.1128/MCB.23.1.104-118.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  52 in total

1.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.

Authors:  S L Anzick; J Kononen; R L Walker; D O Azorsa; M M Tanner; X Y Guan; G Sauter; O P Kallioniemi; J M Trent; P S Meltzer
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

2.  ER beta: identification and characterization of a novel human estrogen receptor.

Authors:  S Mosselman; J Polman; R Dijkema
Journal:  FEBS Lett       Date:  1996-08-19       Impact factor: 4.124

3.  Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF.

Authors:  I J McEwan; J Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

4.  Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract.

Authors:  A Suzuki; A Matsuzawa; T Iguchi
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

5.  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors.

Authors:  H Hong; K Kohli; M J Garabedian; M R Stallcup
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

6.  Androgen receptor-mediated transcriptional regulation in the absence of direct interaction with a specific DNA element.

Authors:  P J Kallio; H Poukka; A Moilanen; O A Jänne; J J Palvimo
Journal:  Mol Endocrinol       Date:  1995-08

7.  Identification of two transcription activation units in the N-terminal domain of the human androgen receptor.

Authors:  G Jenster; H A van der Korput; J Trapman; A O Brinkmann
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

8.  Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.

Authors:  S Yeh; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

9.  Sequence and characterization of a coactivator for the steroid hormone receptor superfamily.

Authors:  S A Oñate; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Science       Date:  1995-11-24       Impact factor: 47.728

10.  A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.

Authors:  Y Kamei; L Xu; T Heinzel; J Torchia; R Kurokawa; B Gloss; S C Lin; R A Heyman; D W Rose; C K Glass; M G Rosenfeld
Journal:  Cell       Date:  1996-05-03       Impact factor: 41.582

View more
  54 in total

Review 1.  The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation.

Authors:  Lars P Van Der Heide; Marco F M Hoekman; Marten P Smidt
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

2.  Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1.

Authors:  Huarui Lu; Ping Liu; Yunqian Pan; Haojie Huang
Journal:  Neoplasia       Date:  2011-09       Impact factor: 5.715

Review 3.  In control of biology: of mice, men and Foxes.

Authors:  Patrick J E C Wijchers; J Peter H Burbach; Marten P Smidt
Journal:  Biochem J       Date:  2006-07-15       Impact factor: 3.857

4.  Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression.

Authors:  Oona Delpuech; Beatrice Griffiths; Philip East; Abdelkader Essafi; Eric W-F Lam; Boudewijn Burgering; Julian Downward; Almut Schulze
Journal:  Mol Cell Biol       Date:  2007-04-23       Impact factor: 4.272

Review 5.  Forkhead transcription factors and cardiovascular biology.

Authors:  Kyriakos N Papanicolaou; Yasuhiro Izumiya; Kenneth Walsh
Journal:  Circ Res       Date:  2008-01-04       Impact factor: 17.367

6.  FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.

Authors:  Laura R Bohrer; Ping Liu; Jian Zhong; Yunqian Pan; James Angstman; Lucas J Brand; Scott M Dehm; Haojie Huang
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

7.  FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment.

Authors:  Qiuping Ma; Wei Fu; Pengfei Li; Santo V Nicosia; Guido Jenster; Xiaohong Zhang; Wenlong Bai
Journal:  Mol Endocrinol       Date:  2008-12-12

Review 8.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

9.  Low-Dose Dihydrotestosterone Drives Metabolic Dysfunction via Cytosolic and Nuclear Hepatic Androgen Receptor Mechanisms.

Authors:  Stanley Andrisse; Shameka Childress; Yaping Ma; Katelyn Billings; Yi Chen; Ping Xue; Ashley Stewart; Momodou L Sonko; Andrew Wolfe; Sheng Wu
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

10.  Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming.

Authors:  Caroline H Diep; Todd P Knutson; Carol A Lange
Journal:  Mol Cancer Res       Date:  2015-11-17       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.